CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells

Wang, Li; Liang, Tingting

doi:10.1186/s13568-020-00990-z

Cited by 31 publications

(17 citation statements)

References 27 publications

(28 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The anticancer effects were only assessed in vitro and demonstrated a full internalization of the complex by tumor cells. As expected and according to previous results [ 42 ], co-delivery of miR-1284 and cisplatin synergistically inhibited cell viability and promoted apoptosis by HMGB1 downregulation [ 104 ]. Given these promising results, future in vivo analysis should be done to evaluate the pre-clinical efficacy of this formulation.…”

Section: Therapeutic Combination Of Icd and Mirnas: A New Opportunitysupporting

confidence: 91%

“…Recently, Wang et al designed another type of nanocarrier to deliver both miR-1284 and cisplatin [ 104 ]. They generated liposomes composed of distearoylphosphatidylcholine (DSPC) succinylphosphatidylethanolamine (DSPE-mPEG), distearoyl-N-(3-carboxy-propionoylpoly (ethyleneglycol) succinyl) phosphatidylethanolamine (DSPE-PEG-COOH), and 1,2-dioleoyl-3-trimethylammoniumpropane (DOTAP) to be loaded with 10% of cisplatin and surface-conjugated with the CD59 antibody.…”

Section: Therapeutic Combination Of Icd and Mirnas: A New Opportunitymentioning

confidence: 99%

See 1 more Smart Citation

Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome

Lamberti

Nigro

Casolaro

et al. 2021

Cancers

View full text Add to dashboard Cite

Immunogenic cell death (ICD) in cancer is a functionally unique regulated form of stress-mediated cell death that activates both the innate and adaptive immune response against tumor cells. ICD makes dying cancer cells immunogenic by improving both antigenicity and adjuvanticity. The latter relies on the spatiotemporally coordinated release or exposure of danger signals (DAMPs) that drive robust antigen-presenting cell activation. The expression of DAMPs is often constitutive in tumor cells, but it is the initiating stressor, called ICD-inducer, which finally triggers the intracellular response that determines the kinetics and intensity of their release. However, the contribution of cell-autonomous features, such as the epigenetic background, to the development of ICD has not been addressed in sufficient depth. In this context, it has been revealed that several microRNAs (miRNAs), besides acting as tumor promoters or suppressors, can control the ICD-associated exposure of some DAMPs and their basal expression in cancer. Here, we provide a general overview of the dysregulation of cancer-associated miRNAs whose targets are DAMPs, through which new molecular mediators that underlie the immunogenicity of ICD were identified. The current status of miRNA-targeted therapeutics combined with ICD inducers is discussed. A solid comprehension of these processes will provide a framework to evaluate miRNA targets for cancer immunotherapy.

show abstract

Section: Therapeutic Combination Of Icd and Mirnas: A New Opportunitysupporting

confidence: 91%

Section: Therapeutic Combination Of Icd and Mirnas: A New Opportunitymentioning

confidence: 99%

Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome

Lamberti

Nigro

Casolaro

et al. 2021

Cancers

View full text Add to dashboard Cite

show abstract

“…Interestingly, the miR-1284 upregulation and the consequent HMGB1 targeting synergized with cisplatin, enhancing the sensitivity of cervical cancer cells to the drug [ 45 ]. The synergisms between miR-1284 and cisplatin were further proved by Wang and colleagues [ 76 ] that used CD59sp-conjugated miRNA-1284/cisplatin-loaded liposomes to target cervical cancer cells, showing dose-dependency and higher performance in killing HeLa cells compared to cisplatin alone. These findings open new perspectives in the use of miR-1284 as a chemosensitizer in cervical cancer ( Figure 3 ).…”

Section: Molecular Mechanisms Associated With Cisplatin Resistancementioning

confidence: 92%

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer

Masadah

Rauf

Pratama

et al. 2021

Cancers

View full text Add to dashboard Cite

Cervical cancer is the fourth leading cause of cancer-related death among women worldwide. The chemotherapeutical agent cisplatin, a small platinum-based compound, is considered as the standard therapy for locally advanced cervical cancer or recurrent cancers, sometimes in combination with radiotherapy or other drugs. However, drug resistance and radio-resistance phenomena could reduce the life expectancy of cervical cancer patients. Resistance mechanisms are complex and often involve multiple cellular pathways in which microRNAs (miRNAs) play a fundamental role. MiRNAs are a class of endogenous non-coding small RNAs responsible for post-transcriptional gene regulation. Convincing evidence demonstrates that several deregulated miRNAs are important regulators in the onset of drug and radioresistance in cervical cancer, thus underlying their potential applications in a clinical setting. In this review, we summarized the mechanisms by which miRNAs affect both cisplatin and radioresistance in cervical cancer. We also described the regulatory loops between miRNAs and lncRNAs promoting drug resistance. Besides, we reported evidence for the role of miRNAs in sensitizing cancer cells to cisplatin-based chemotherapy, and provided some suggestions for the development of new combined therapies for cervical cancer.

show abstract

“…Finally, they are positively charged in an acidic environment (i.e., endosomes) leading to the association to anionic endosomal lipids and consequently the release of the payload in the cytosol [ 61 , 64 ]. Such formulations were demonstrated to be efficient in the in vitro delivery of siRNAs [ 67 ] and in vivo release of miRNAs [ 68 , 69 , 70 ], alone or in combination with other therapeutics, and ASOs [ 71 ].…”

Section: Platforms For the Delivery Of Oligonucleotides (Ons)mentioning

confidence: 99%

Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model

Toffoli

Macor

et al. 2021

Pharmaceutics

View full text Add to dashboard Cite

Oligonucleotide (ON) therapeutics are molecular target agents composed of chemically synthesized DNA or RNA molecules capable of inhibiting gene expression or protein function. How ON therapeutics can efficiently reach the inside of target cells remains a problem still to be solved in the majority of potential clinical applications. The chemical structure of ON compounds could affect their capability to pass through the plasma membrane. Other key factors are nuclease degradation in the extracellular space, renal clearance, reticulo-endothelial system, and at the target cell level, the endolysosomal system and the possible export via exocytosis. Several delivery platforms have been proposed to overcome these limits including the use of lipidic, polymeric, and inorganic nanoparticles, or hybrids between them. The possibility of evaluating the efficacy of the proposed therapeutic strategies in useful in vivo models is still a pivotal need, and the employment of zebrafish (ZF) models could expand the range of possibilities. In this review, we briefly describe the main ON therapeutics proposed for anticancer treatment, and the different strategies employed for their delivery to cancer cells. The principal features of ZF models and the pros and cons of their employment in the development of ON-based therapeutic strategies are also discussed.

show abstract

CD59 receptor targeted delivery of miRNA-1284 and cisplatin-loaded liposomes for effective therapeutic efficacy against cervical cancer cells

Cited by 31 publications

References 27 publications

Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome

Damage-Associated Molecular Patterns Modulation by microRNA: Relevance on Immunogenic Cell Death and Cancer Treatment Outcome

The Role of microRNAs in the Cisplatin- and Radio-Resistance of Cervical Cancer

Nanoparticles-Based Oligonucleotides Delivery in Cancer: Role of Zebrafish as Animal Model

Contact Info

Product

Resources

About